S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
META's Outperformance Last Week Points to Imminent Breakout
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
META's Outperformance Last Week Points to Imminent Breakout
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
META's Outperformance Last Week Points to Imminent Breakout
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Would Buffett Approve of This Growth Strategy? (Ad)
META's Outperformance Last Week Points to Imminent Breakout
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
OTCMKTS:RCDTF

Recordati Industria Chimica e Farmaceutica (RCDTF) Stock Forecast, Price & News

$46.00
-0.82 (-1.75%)
(As of 08/7/2023)
Compare
Today's Range
$46.00
▼
$46.00
50-Day Range
$46.00
▼
$46.82
52-Week Range
$46.00
▼
$50.00
Volume
300 shs
Average Volume
175 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest

RCDTF stock logo

About Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Stock

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

RCDTF Price History

RCDTF Stock News Headlines

September 9, 2023 | forbes.com
Fondo pensione: cos’è e come funziona
July 21, 2023 | msn.com
Borsa: Milano positiva con le banche, vola Recordati
September 25, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
May 12, 2023 | msn.com
Italy's Recordati boosted by strong sales in Russia
May 11, 2023 | msn.com
Recordati GAAP EPS of €0.59, revenue of €551.4M
May 11, 2023 | msn.com
Recordati ups guidance on strong growth in specialty, primary care markets
April 21, 2023 | msn.com
Recordati, nel primo trimestre ricavi per 551,4 milioni di euro (+31,5%). Ok dei soci al buy back da massimi 200 milioni
February 21, 2023 | reuters.com
Recordati shares fall after core profit margin forecasts disappoint
September 25, 2023 | Edge On The Street (Ad)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
February 17, 2023 | msn.com
Recordati bocciata da Barclays. Che taglia il prezzo obiettivo da 40 a 35 euro
January 23, 2023 | reuters.com
RECItah.MI
January 14, 2023 | businesswire.com
Cresce l'espansione di AESARA Europe con la nomina di Patrizia Berto, una veterana dell'industria farmaceutica italiana
November 8, 2022 | msn.com
Recordati alza la guidance per il 2022. Acconto del dividendo pari a 0,55 euro
October 28, 2022 | finanznachrichten.de
Sherwin-Williams To Buy Italian Wood Coatings Firm Industria Chimica Adriatica
September 27, 2022 | finance.yahoo.com
Recordati Industria Chimica e Farmaceutica S.p.A. (0KBS.L)
September 18, 2022 | finance.yahoo.com
Recordati Industria Chimica e Farmaceutica S.p.A. (REC.VI)
September 8, 2022 | finance.yahoo.com
Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)
August 31, 2022 | finance.yahoo.com
Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology
July 30, 2022 | seekingalpha.com
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q2 2022 Results - Earnings Call Transcript
June 16, 2022 | apnews.com
Recordati Rare Diseases Announces Positive Data From Phase III Linc 4, Phase III Linc 3, and Illustrate ISTURISA® Studies Presented at ENDO 2022
June 8, 2022 | finance.yahoo.com
Recordati Rare Diseases Announces Several Scientific Abstracts to Be Presented at the Upcoming Endo Society Annual Meeting
May 14, 2022 | seekingalpha.com
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q1 2022 Results - Earnings Call Transcript
May 10, 2022 | uk.news.yahoo.com
Recordati confirms 2022 targets despite Ukraine conflict
May 10, 2022 | finance.yahoo.com
Recordati Rare Diseases Announces Multiple Scientific Abstracts to Be Highlighted at American Association of Clinical Endocrinology
March 29, 2022 | finance.yahoo.com
Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease
February 26, 2022 | it.investing.com
Recordati manca previsioni degli analisti
February 25, 2022 | seekingalpha.com
Recordati reports FY results
See More Headlines
Receive RCDTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter.

RCDTF Company Calendar

Today
9/25/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:RCDTF
Previous Symbol
NASDAQ:RCDTF
CUSIP
N/A
CIK
N/A
Web
www.recordati.com
Phone
390-248-7871
Fax
39-02-4007-3747
Employees
4,303
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.87 billion
Price / Sales
N/A
Cash Flow
$2.99 per share
Price / Cash Flow
15.36
Book Value
$7.92 per share
Price / Book
5.81

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.29
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Robert Koremans M.D. (Age 61)
    CEO & Director
    Comp: $1.93M
  • Mr. Luigi Felice La Corte (Age 54)
    Group CFO & Exec. Director
    Comp: $1.01M
  • Ms. Cathrin Petty (Age 50)
    Exec. Director
  • Mr. Giampiero Mazza (Age 54)
    Exec. Director
  • Mr. Giorgio De Palma (Age 49)
    Exec. Director
  • Ms. Federica De Medici
    Director of Investor Relations & Corp. Communications
  • Ms. Bibianne Bon
    Group Chief Legal Officer
  • Mr. Gabriele Finzi
    Exec. VP of Corp. Devel., Licensing & Innovation
  • Mr. Giuseppe Gualazzini (Age 64)
    Sr. VP of Group HR
  • Mr. Roberto Teruzzi
    Exec. VP of Group Industrial Operations

Key Competitors

View All Competitors













RCDTF Stock - Frequently Asked Questions

Should I buy or sell Recordati Industria Chimica e Farmaceutica stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Recordati Industria Chimica e Farmaceutica in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RCDTF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RCDTF, but not buy additional shares or sell existing shares.
View RCDTF analyst ratings or view top-rated stocks.

How have RCDTF shares performed in 2023?

Recordati Industria Chimica e Farmaceutica's stock was trading at $40.93 on January 1st, 2023. Since then, RCDTF shares have increased by 12.4% and is now trading at $46.00.
View the best growth stocks for 2023 here.

What is Recordati Industria Chimica e Farmaceutica's stock symbol?

Recordati Industria Chimica e Farmaceutica trades on the OTCMKTS under the ticker symbol "RCDTF."

How do I buy shares of Recordati Industria Chimica e Farmaceutica?

Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Recordati Industria Chimica e Farmaceutica's stock price today?

One share of RCDTF stock can currently be purchased for approximately $46.00.

How many employees does Recordati Industria Chimica e Farmaceutica have?

The company employs 4,303 workers across the globe.

How can I contact Recordati Industria Chimica e Farmaceutica?

Recordati Industria Chimica e Farmaceutica's mailing address is Via Matteo Civitali 1, Milano L6, 20148. The official website for the company is www.recordati.com. The company can be reached via phone at 390-248-7871, via email at investorelations@recordati.it, or via fax at 39-02-4007-3747.

This page (OTCMKTS:RCDTF) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -